{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:35:00Z","timestamp":1791848100978,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R15CA271221-01A1"],"award-info":[{"award-number":["1R15CA271221-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018135","name":"Albany College of Pharmacy and Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>ER positive breast cancer is currently targeted using various endocrine therapies. Despite the proven therapeutic efficacy, resistance to the drug and reoccurrence of tumor appears to be a complication that many patients deal with. Molecular pathways underlying the development of resistance are being widely studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this study, using four established endocrine resistant breast cancer (ERBC) cell lines, we characterized CXCL1 as a secreted factor in crosstalk between ERBC cells and fibroblasts. Protein array revealed upregulation of CXCL1 and we confirmed the CXCL1 expression by real-time qRT-PCR and U-Plex assay. Co-culturing ERBC cells with fibroblasts enhanced the cell growth and migration compared to monoculture. The crosstalk of ERBC cells with fibroblasts significantly activates ERK\/MAPK signaling pathway while reparixin, CXCR1\/2 receptor inhibitor, attenuates the activity. Reparixin displayed the ERBC cell growth inhibition and the combination treatment with reparixin and CDK4\/6 inhibitor (palbociclib and ribociclib) increased these inhibitory effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1\/2 and CDK4\/6 could potentially overcome endocrine resistant breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-023-09119-4","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T09:06:46Z","timestamp":1708679206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast"],"prefix":"10.1007","volume":"51","author":[{"given":"Sneha","family":"Pandithar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Galke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahone","family":"Akume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Belyakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Lomonaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirah A.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Reff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6898-2512","authenticated-orcid":false,"given":"Kideok","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"Suppl 2","key":"9119_CR1","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","volume":"24","author":"A Nardone","year":"2015","unstructured":"Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R (2015) The changing role of ER in endocrine resistance. Breast 24(Suppl 2):S60\u2013S66. https:\/\/doi.org\/10.1016\/j.breast.2015.07.015","journal-title":"Breast"},{"issue":"21","key":"9119_CR2","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin D, Gu G, Fuqua SAW (2019) ESR1 mutations in breast cancer. Cancer 125(21):3714\u20133728. https:\/\/doi.org\/10.1002\/cncr.32345","journal-title":"Cancer"},{"issue":"4","key":"9119_CR3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA (2021) Therapeutic targeting of the tumor microenvironment. Cancer Discov 11(4):933\u2013959. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1808","journal-title":"Cancer Discov"},{"issue":"4","key":"9119_CR4","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC (2021) Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov 11(4):874\u2013899. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1638","journal-title":"Cancer Discov"},{"issue":"5","key":"9119_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392\u2013401. https:\/\/doi.org\/10.1038\/nrc1877","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"9119_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R (2021) Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol 18(12):792\u2013804. https:\/\/doi.org\/10.1038\/s41571-021-00546-5","journal-title":"Nat Rev Clin Oncol"},{"key":"9119_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020792","author":"J Korbecki","year":"2022","unstructured":"Korbecki J, Barczak K, Gutowska I, Chlubek D, Baranowska-Bosiacka I (2022) Gene, promoter, regulation of expression, mRNA stability, regulation of activity in the intercellular space. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23020792","journal-title":"Int J Mol Sci"},{"issue":"4","key":"9119_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cns.13297","volume":"26","author":"W Alafate","year":"2020","unstructured":"Alafate W, Li X, Zuo J, Zhang H, Xiang J, Wu W, Xie W, Bai X, Wang M, Wang J (2020) Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma. CNS Neurosci Ther 26(4):475\u2013485. https:\/\/doi.org\/10.1111\/cns.13297","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"9119_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1724600820914944","volume":"35","author":"D Wang","year":"2020","unstructured":"Wang D, Luo Y, Guo Y, Li G, Li F (2020) A-kinase interacting protein 1, a potential biomarker associated with advanced tumor features and CXCL1\/2 in prostate cancer. Int J Biol Markers 35(2):74\u201381. https:\/\/doi.org\/10.1177\/1724600820914944","journal-title":"Int J Biol Markers"},{"key":"9119_CR10","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180580","author":"C Zhuo","year":"2018","unstructured":"Zhuo C, Wu X, Li J, Hu D, Jian J, Chen C, Zheng X, Yang C (2018) Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20180580"},{"issue":"1","key":"9119_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4149\/neo_2015_020","volume":"62","author":"L Han","year":"2015","unstructured":"Han L, Liu W, Chen Y, Wu H, Zhang Y, Jiang B (2015) GRO\u03b1 expression and its prognostic implications in laryngeal squamous cell carcinoma. Neoplasma 62(1):152\u2013158. https:\/\/doi.org\/10.4149\/neo_2015_020","journal-title":"Neoplasma"},{"key":"9119_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1186\/1471-2407-14-781","volume":"14","author":"A Zou","year":"2014","unstructured":"Zou A, Lambert D, Yeh H, Yasukawa K, Behbod F, Fan F, Cheng N (2014) Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-\u03b2 signaling proteins. BMC Cancer 14:781. https:\/\/doi.org\/10.1186\/1471-2407-14-781","journal-title":"BMC Cancer"},{"issue":"4","key":"9119_CR13","first-page":"1491","volume":"33","author":"R Divella","year":"2013","unstructured":"Divella R, Daniele A, Savino E, Palma F, Bellizzi A, Giotta F, Simone G, Lioce M, Quaranta M, Paradiso A, Mazzocca A (2013) Circulating levels of transforming growth factor-\u03b2eta (TGF-\u03b2) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer. Anticancer Res 33(4):1491\u20131497","journal-title":"Anticancer Res"},{"issue":"9","key":"9119_CR14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41419-018-0876-3","volume":"9","author":"N Wang","year":"2018","unstructured":"Wang N, Liu W, Zheng Y, Wang S, Yang B, Li M, Song J, Zhang F, Zhang X, Wang Q, Wang Z (2018) CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-\u03baB\/SOX4 signaling. Cell Death Dis 9(9):880. https:\/\/doi.org\/10.1038\/s41419-018-0876-3","journal-title":"Cell Death Dis"},{"key":"9119_CR15","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3389\/fimmu.2019.01574","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhang H, He YW (2019) The complement receptors C3aR and C5aR are a new class of immune checkpoint receptor in cancer immunotherapy. Front Immunol 10:1574. https:\/\/doi.org\/10.3389\/fimmu.2019.01574","journal-title":"Front Immunol"},{"issue":"11","key":"9119_CR16","first-page":"2112","volume":"19","author":"XY Li","year":"2015","unstructured":"Li XY, Hu SQ, Xiao L (2015) The cancer-associated fibroblasts and drug resistance. Eur Rev Med Pharmacol Sci 19(11):2112\u20132119","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"9119_CR17","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1111\/cas.14578","volume":"111","author":"L Bu","year":"2020","unstructured":"Bu L, Baba H, Yasuda T, Uchihara T, Ishimoto T (2020) Functional diversity of cancer-associated fibroblasts in modulating drug resistance. Cancer Sci 111(10):3468\u20133477. https:\/\/doi.org\/10.1111\/cas.14578","journal-title":"Cancer Sci"},{"issue":"1","key":"9119_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0039-128x(02)00110-1","volume":"68","author":"DA Lannigan","year":"2003","unstructured":"Lannigan DA (2003) Estrogen receptor phosphorylation. Steroids 68(1):1\u20139. https:\/\/doi.org\/10.1016\/s0039-128x(02)00110-1","journal-title":"Steroids"},{"issue":"1","key":"9119_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/or.2014.3190","volume":"32","author":"R Viedma-Rodriguez","year":"2014","unstructured":"Viedma-Rodriguez R, Baiza-Gutman L, Salamanca-Gomez F, Diaz-Zaragoza M, Martinez-Hernandez G, Ruiz Esparza-Garrido R, Velazquez-Flores MA, Arenas-Aranda D (2014) Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep 32(1):3\u201315. https:\/\/doi.org\/10.3892\/or.2014.3190","journal-title":"Oncol Rep"},{"issue":"15","key":"9119_CR20","first-page":"3331","volume":"55","author":"SR Johnston","year":"1995","unstructured":"Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M (1995) Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55(15):3331\u20133338","journal-title":"Cancer Res"},{"issue":"3","key":"9119_CR21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3892\/ijo.2019.4840","volume":"55","author":"C Yang","year":"2019","unstructured":"Yang C, Yu H, Chen R, Tao K, Jian L, Peng M, Li X, Liu M, Liu S (2019) CXCL1 stimulates migration and invasion in ER-negative breast cancer cells via activation of the ERK\/MMP2\/9 signaling axis. Int J Oncol 55(3):684\u2013696. https:\/\/doi.org\/10.3892\/ijo.2019.4840","journal-title":"Int J Oncol"},{"issue":"6","key":"9119_CR22","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.4049\/jimmunol.1201114","volume":"189","author":"SK Raghuwanshi","year":"2012","unstructured":"Raghuwanshi SK, Su Y, Singh V, Haynes K, Richmond A, Richardson RM (2012) The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol 189(6):2824\u20132832. https:\/\/doi.org\/10.4049\/jimmunol.1201114","journal-title":"J Immunol"},{"issue":"1","key":"9119_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-022-01510-6","volume":"24","author":"AC Watt","year":"2022","unstructured":"Watt AC, Goel S (2022) Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res 24(1):17. https:\/\/doi.org\/10.1186\/s13058-022-01510-6","journal-title":"Breast Cancer Res"},{"key":"9119_CR24","doi-asserted-by":"publisher","first-page":"153303382311735","DOI":"10.1177\/15330338231173504","volume":"22","author":"W Wang","year":"2023","unstructured":"Wang W, Wu J, Chen K, Wang X, Shao X (2023) Prognostic parameters of Palbociclib in HR+\/HER2- advanced breast cancer: a narrative review. Technol Cancer Res Treat 22:15330338231173504. https:\/\/doi.org\/10.1177\/15330338231173504","journal-title":"Technol Cancer Res Treat"},{"key":"9119_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184558","author":"JJ Zhao","year":"2023","unstructured":"Zhao JJ, Fong KY, Chan YH, Tey J, Dawood S, Lee SC, Finn RS, Sundar R, Lim JSJ (2023) Indirect treatment comparison of first-line CDK4\/6-inhibitors in post-menopausal patients with HR+\/HER2- metastatic breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15184558","journal-title":"Cancers (Basel)"},{"issue":"12","key":"9119_CR26","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4155\/fmc.15.93","volume":"7","author":"W Fan","year":"2015","unstructured":"Fan W, Chang J, Fu P (2015) Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Fut Med Chem 7(12):1511\u20131519. https:\/\/doi.org\/10.4155\/fmc.15.93","journal-title":"Fut Med Chem"},{"issue":"3","key":"9119_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","volume":"6","author":"F Lumachi","year":"2015","unstructured":"Lumachi F, Santeufemia DA, Basso SM (2015) Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem 6(3):231\u2013239. https:\/\/doi.org\/10.4331\/wjbc.v6.i3.231","journal-title":"World J Biol Chem"},{"issue":"11","key":"9119_CR28","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1158\/0008-5472.CAN-06-4582","volume":"67","author":"M Sui","year":"2007","unstructured":"Sui M, Huang Y, Park BH, Davidson NE, Fan W (2007) Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 67(11):5337\u20135344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4582","journal-title":"Cancer Res"},{"key":"9119_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","volume":"116","author":"N Fuentes","year":"2019","unstructured":"Fuentes N, Silveyra P (2019) Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol 116:135\u2013170. https:\/\/doi.org\/10.1016\/bs.apcsb.2019.01.001","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"5","key":"9119_CR30","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3892\/or.2016.4660","volume":"35","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Jiang YC, Sun CK, Chen QM (2016) Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep 35(5):2499\u20132515. https:\/\/doi.org\/10.3892\/or.2016.4660","journal-title":"Oncol Rep"},{"key":"9119_CR31","doi-asserted-by":"publisher","first-page":"204946","DOI":"10.1155\/2012\/204946","volume":"2012","author":"T Duong","year":"2012","unstructured":"Duong T, Koopman P, Francois M (2012) Tumor lymphangiogenesis as a potential therapeutic target. J Oncol 2012:204946. https:\/\/doi.org\/10.1155\/2012\/204946","journal-title":"J Oncol"},{"issue":"8A","key":"9119_CR32","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/j.1582-4934.2009.00834.x","volume":"13","author":"V Mumprecht","year":"2009","unstructured":"Mumprecht V, Detmar M (2009) Lymphangiogenesis and cancer metastasis. J Cell Mol Med 13(8A):1405\u20131416. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00834.x","journal-title":"J Cell Mol Med"},{"issue":"2","key":"9119_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1593\/neo.121638","volume":"15","author":"E Lee","year":"2013","unstructured":"Lee E, Koskimaki JE, Pandey NB, Popel AS (2013) Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia 15(2):112\u2013124","journal-title":"Neoplasia"},{"key":"9119_CR34","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1038\/ncomms5715","volume":"5","author":"E Lee","year":"2014","unstructured":"Lee E, Fertig EJ, Jin K, Sukumar S, Pandey NB, Popel AS (2014) Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat Commun 5:4715. https:\/\/doi.org\/10.1038\/ncomms5715","journal-title":"Nat Commun"},{"issue":"1","key":"9119_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13058-018-0981-3","volume":"20","author":"K Jin","year":"2018","unstructured":"Jin K, Pandey NB, Popel AS (2018) Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Res 20(1):54. https:\/\/doi.org\/10.1186\/s13058-018-0981-3","journal-title":"Breast Cancer Res"},{"issue":"36","key":"9119_CR36","doi-asserted-by":"publisher","first-page":"60210","DOI":"10.18632\/oncotarget.19417","volume":"8","author":"K Jin","year":"2017","unstructured":"Jin K, Pandey NB, Popel AS (2017) Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis. Oncotarget 8(36):60210\u201360222. https:\/\/doi.org\/10.18632\/oncotarget.19417","journal-title":"Oncotarget"},{"issue":"1","key":"9119_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","volume":"150","author":"S Acharyya","year":"2012","unstructured":"Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massague J (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150(1):165\u2013178. https:\/\/doi.org\/10.1016\/j.cell.2012.04.042","journal-title":"Cell"},{"issue":"5","key":"9119_CR38","first-page":"216","volume":"32","author":"M Shah","year":"2018","unstructured":"Shah M, Nunes MR, Stearns V (2018) CDK4\/6 inhibitors: game changers in the management of hormone receptor-positive advanced breast cancer? Oncology (Williston Park) 32(5):216\u2013222","journal-title":"Oncology (Williston Park)"},{"key":"9119_CR39","doi-asserted-by":"publisher","first-page":"891580","DOI":"10.3389\/fonc.2022.891580","volume":"12","author":"GL Rampioni Vinciguerra","year":"2022","unstructured":"Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall\u2019Acqua A, Vecchione A, Baldassarre G, Belletti B (2022) CDK4\/6 inhibitors in combination therapies: better in company than alone: a mini review. Front Oncol 12:891580. https:\/\/doi.org\/10.3389\/fonc.2022.891580","journal-title":"Front Oncol"},{"issue":"9","key":"9119_CR40","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-15-0090","volume":"5","author":"K Jin","year":"2015","unstructured":"Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T, Gyorffy B, Goswami CP, Nakshatri H, Cruz LA, Zhou W, Ji H, Su Y, Ekram M, Wu Z, Zhu T, Polyak K, Sukumar S (2015) HOXB7 Is an ERalpha cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. Cancer Discov 5(9):944\u2013959. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0090","journal-title":"Cancer Discov"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-09119-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-09119-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-09119-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:04:00Z","timestamp":1738685040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-09119-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9119"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-09119-4","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}],"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2475331\/v1","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"331"}}